AstraZeneca, Handa Settle Seroquel Patent Fight

Law360, New York (September 29, 2011, 6:08 PM EDT) -- AstraZeneca Pharmaceuticals Inc. announced Thursday that it had reached a settlement with rival Handa Pharmaceuticals LLC in several suits in New Jersey over Handa's bid to produce a generic version of the schizophrenia drug Seroquel XR.

Under the agreement, AstraZeneca will license Handa to enter the U.S. market with a generic version of Seroquel XR on Nov. 1, 2016. AstraZeneca's patents for the drug range in expiration dates from March 2012 to November 2017.

"We believe this agreement reaffirms our intellectual property rights and is the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.